Colossal Biosciences Unicorn Score: 79/100
Colossal Biosciences is a biotechnology and genetic engineering company focused on de-extinction and species preservation. It aims to revive extinct animals like the woolly mammoth, Tasmanian tiger, and dodo, leveraging advanced genetic technologies such as CRISPR. The company also develops genomic modeling software and reproductive technologies for broader conservation biology applications.
Valuation track record
- First screened
- May 31, 2026
- Entry valuation
- $10B
- Current valuation
- $10B
Latest valuation verified from Live re-screening on May 31, 2026. Re-verified quarterly from public funding announcements.
Founders
Ben Lamm
Co-Founder and CEO
George Church
Founder
Get the full Colossal Biosciences report
Founders deep-dive, traction signals, market thesis, red flags, scoring breakdown and an audio summary, delivered to your inbox.
Frequently asked
What is Colossal Biosciences's unicorn score?
Colossal Biosciences has a Unicorn Screener score of 79/100, classified as "High Potential". Recommended action: buy.
What is Colossal Biosciences's current valuation?
Colossal Biosciences's most recently verified valuation is $10B, last checked on May 31, 2026 (source: Live re-screening).
What sector is Colossal Biosciences in?
Colossal Biosciences operates in the Biotech sector and is headquartered in Dallas, United States.
When was Colossal Biosciences first screened?
Colossal Biosciences was first screened by Unicorn Screener on May 31, 2026, with an entry valuation of $10B.